OmniAb, Inc. (OABI) vs Zevra Therapeutics, Inc. (ZVRA)
A side-by-side comparison of OmniAb, Inc. and Zevra Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OABI
OmniAb, Inc.
$4.35HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZVRA
Zevra Therapeutics, Inc.
$10.73HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — OABI vs ZVRA
growth of $100 · dividends reinvested · last 5yOABI -49.6% (-12.8%/yr)ZVRA +16.9% (+3.2%/yr)ZVRA compounded faster over this window
OABI ZVRA
OABI vs ZVRA: by the numbers
- •ZVRA is the larger company ($634M vs $631M market cap).
- •ZVRA is profitable (42.82% net margin) while OABI runs a net loss (-115.18%).
- •ZVRA grew revenue faster over the past five years (36.81% vs -4.31% CAGR).
Metrics side by side
Valuation
| Metric | OABI | ZVRA |
|---|---|---|
| P/E ratio | N/A | 11.53 |
| Forward P/E | N/A | 9.68 |
| P/S ratio | 16.41 | 4.66 |
| P/B ratio | 2.42 | 2.91 |
| EV / EBITDA | N/A | 12.11 |
| FCF yield | N/A | 5.13% |
Profitability
| Metric | OABI | ZVRA |
|---|---|---|
| Gross margin | -18.17% | 84.52% |
| Operating margin | -383.15% | -3.98% |
| Net margin | -115.18% | 42.82% |
| ROE | -17.01% | 26.77% |
| ROIC | -17.48% | 12.93% |
Growth (annualized)
| Metric | OABI | ZVRA |
|---|---|---|
| Revenue CAGR (5Y) | -4.31% | 36.81% |
| Total return CAGR (5Y) | -13.17% | 3.75% |
Frequently asked
- Which has grown faster, OABI or ZVRA?
- Over the past five years, ZVRA grew revenue faster — OABI at a -4.31% CAGR versus ZVRA at 36.81%.
- Is OABI or ZVRA more profitable?
- ZVRA runs the higher net margin — OABI at -115.18% versus ZVRA at 42.82%.
- How have OABI and ZVRA total returns compared?
- Over the past 5 years, OABI delivered -13.17% and ZVRA delivered 3.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Zevra Therapeutics P/E ratioOmniAb ROEZevra Therapeutics ROEOmniAb operating marginZevra Therapeutics operating marginOmniAb revenue growthZevra Therapeutics revenue growthOmniAb free cash flowZevra Therapeutics free cash flow
OmniAb & Zevra Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.